In the quiet, ongoing effort to tame diseases that turn the body's own defenses against its organs, Vera Therapeutics has asked United States regulators to allow its experimental drug atacicept to be used by adults living with immunoglobulin A nephropathy, a condition in which the kidneys slowly suffer from immune deposits. The request rests on early evidence that the drug reduces protein leaking into the urine and helps preserve kidney filtering function, with a safety profile resembling placebo so far. Whether this early signal will become a treatment that reaches patients sooner, under the
Vera Therapeutics Seeks FDA Accelerated Approval for Atacicept in IgA Nephropathy
A kidney disease drug asks the FDA for a faster path
Mark
So what exactly has Vera done here?
Mimi
It submitted a Biologics License Application to the FDA for atacicept in adults with IgA nephropathy, using the Accelerated Approval Program.
Mark
What is the filing built on?
Mimi
A prespecified interim analysis of the OriginIN 3 trial, which met its primary endpoint of reduced proteinuria at week 36.
Luke
Worth noting that's an interim analysis, and proteinuria is an early marker, not the final outcome. Accelerated approval exists for that reason.
Mark
And the earlier Phase 2b data?
Mimi
Proteinuria reductions and stable eGFR versus placebo through 36 weeks, with safety comparable to placebo during the randomized period.
Luke
Those results are the company's characterization. The announcement doesn't give us the actual numbers, so I can't say how large the effect is.
Mark
The drug has Breakthrough Therapy Designation too.
Mimi
Yes, the FDA concluded it may substantially improve on available therapies. That's a regulator's view, not an approval.
Luke
Right, and 'best-in-class potential' is Vera's belief, not a finding. Whether the FDA grants approval is unknown.
Mark
What's the bigger horizon?
Mimi
The PIONEER trial is testing atacicept in membranous nephropathy, FSGS and minimal change disease, and ORIGIN Extend keeps earlier participants on the drug.
Il Polso
- A filing has landed at the FDA, asking for accelerated approval of atacicept for adults with IgA nephropathy on the strength of an interim trial read-out.
- The central measure is proteinuria, the leakage of protein into urine, which fell at week 36 in the OriginIN 3 analysis.
- Earlier ORIGIN Phase 2b results showed stabilized kidney filtering function against placebo, with safety that looked comparable to placebo.
- The FDA has already granted Breakthrough Therapy Designation, a signal of regulatory confidence that shortens the path ahead.
- Review decisions and PIONEER results in membranous nephropathy and FSGS/minimal change disease will determine whether the drug moves from promise to prescription.
In the quiet, ongoing effort to tame diseases that turn the body's own defenses against its organs, Vera Therapeutics has asked United States regulators to allow its experimental drug atacicept to be used by adults living with immunoglobulin A nephropathy, a condition in which the kidneys slowly suffer from immune deposits. The request rests on early evidence that the drug reduces protein leaking into the urine and helps preserve kidney filtering function, with a safety profile resembling placebo so far. Whether this early signal will become a treatment that reaches patients sooner, under the accelerated pathway built for promising medicines, now rests with the Food and Drug Administration.
Vera Therapeutics has formally asked the U.S. Food and Drug Administration to approve atacicept, its experimental medicine for adults with immunoglobulin A nephropathy, a kidney disease in which the immune system damages the organs it should protect. The company submitted a Biologics License Application under the Accelerated Approval Program, a route designed to bring promising treatments to patients sooner by relying on an early measure of benefit.
The application rests on a prespecified interim analysis of the OriginIN 3 trial, which Vera says met its primary endpoint: a reduction in proteinuria at week 36. This builds on the earlier ORIGIN Phase 2b study, where the company reports meaningful drops in protein leakage, stabilized kidney filtering function compared with placebo through 36 weeks, and a safety profile comparable to placebo during the randomized portion.
Atacicept works by targeting B cells and the signaling molecules that keep them producing the autoantibodies linked to the disease. The FDA has already granted it Breakthrough Therapy Designation for IgAN, a recognition that the drug may offer substantial improvement over existing options. Participants from the earlier studies remain connected through the ORIGIN Extend study, which offers continued access until the drug may become available in their region.
Vera is also widening its view through the PIONEER trial, which is testing atacicept in broader IgAN populations, in anti-PLA2R positive membranous nephropathy, and in anti-nephrin positive FSGS and minimal change disease. What comes next is the FDA's review and whether it grants accelerated approval, along with those further results.
Vera Therapeutics has formally asked the U.S. Food and Drug Administration to approve atacicept, its experimental drug for adults with immunoglobulin A nephropathy, a kidney disease driven by the immune system. The company announced that it submitted a Biologics License Application, and that it is using the Accelerated Approval Program, a pathway built to bring promising therapies to patients sooner on the strength of an early measure of benefit.
The filing rests on a prespecified interim analysis of a trial called OriginIN 3. According to the company, that analysis met its primary endpoint: a reduction in proteinuria, the leakage of protein into the urine, measured at week 36.
That result builds on earlier work. The ORIGIN Phase 2b trial of atacicept in IgAN met its primary and key secondary endpoints, according to Vera, with statistically significant and clinically meaningful reductions in proteinuria. The same trial showed stabilization of eGFR, a measure of kidney filtering function, compared with placebo through 36 weeks. During the randomized portion of the study, the safety profile of atacicept was comparable to placebo. Vera says that across the ORIGIN program in IgAN, the safety picture appears favorable and in line with placebo.
Atacicept works by targeting B cells to reduce the autoantibodies tied to the disease. It acts on cytokines in the tumor necrosis factor family that promote B-cell survival and autoantibody production, a mechanism linked to IgAN, lupus nephritis and other autoimmune kidney diseases. Vera notes that more than 1,500 patients have received atacicept in clinical trials across various disease areas, and the company believes the drug has best-in-class potential. That is Vera's own assessment, not a regulatory finding.
The FDA has, however, already granted atacicept Breakthrough Therapy Designation for IgAN. That designation reflects the agency's determination, based on the ORIGIN Phase 2b data, that the drug may offer substantial improvement over available therapies on a clinically significant endpoint.
People who took part in the earlier studies have a continuing connection to the drug. The ORIGIN Extend study gives ORIGIN participants extended access to atacicept until it might become commercially available in their region, and it collects longer-term safety and efficacy data along the way.
Vera is also looking beyond the current IgAN population. The PIONEER trial is evaluating atacicept in expanded IgAN populations, in anti-PLA2R positive primary membranous nephropathy, and in patients with anti-nephrin positive focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
What comes next is the FDA's review of the application, including whether it grants accelerated approval, along with results from the PIONEER studies in the additional kidney diseases.
Citazioni salienti
Vera believes atacicept is positioned for best-in-class potential by targeting B cells to reduce autoantibodies.— Vera Therapeutics
Vuoi la storia completa?
Leggi l'originale su MarketScreener ↗
Health & Medicine